Rev Therapeutics is developing an oral small‑molecule inhibitor that targets the molecular pathways of renal ischemia‑reperfusion injury to prevent or lessen acute kidney injury after cardiac surgery. The drug is designed for rapid peri‑operative dosing and can be integrated into existing cardiac surgery protocols, aiming to preserve kidney function, reduce intensive‑care stays, and improve patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Patients undergoing cardiac surgery frequently develop acute kidney injury (AKI), leading to increased morbidity, prolonged hospital stays, and higher mortality rates. Current treatments do not specifically target the molecular mechanisms that cause postoperative renal damage.
Solution
Rev Therapeutics is developing a novel small‑molecule inhibitor designed to prevent or mitigate AKI that occurs after cardiac surgery. The compound modulates key molecular pathways implicated in renal ischemia‑reperfusion injury, aiming to preserve kidney function during the peri‑operative period. By intervening early, the therapy seeks to reduce postoperative complications, shorten intensive care stays, and improve overall patient outcomes for cardiac surgery recipients.
Target Audience
Primary customers are cardiac surgery centers and hospitals seeking pharmacologic strategies to reduce postoperative AKI in patients undergoing coronary artery bypass grafting, valve replacement, and other major cardiac procedures.
Features
- Small‑molecule oral formulation optimized for rapid onset and peri‑operative dosing
- Targeted inhibition of specific signaling cascades involved in renal ischemia‑reperfusion injury
- Preclinical data demonstrating renal protection and preservation of glomerular filtration rate
- Designed for integration into existing cardiac surgery care pathways without additional equipment